Macular Degeneration News and Research

Latest Macular Degeneration News and Research

University of Kentucky researchers make major breakthrough in GA

University of Kentucky researchers, led by Dr. Jayakrishna Ambati, have made a major breakthrough in the "dry" form of age-related macular degeneration known as geographic atrophy.

27 Apr 2012

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

A team led by a scientist from The Scripps Research Institute has been awarded a five-year, $10.2 million grant from the National Eye Institute (NEI) to develop a new type of treatment for diabetic retinopathy, macular degeneration, and other common vision disorders.

23 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

ACT announces dosing of third patient in dry AMD Phase I/II trial

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of the third patient in its Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells.

21 Apr 2012

Regenerative medicine research offers hope for the blind

The University College London researchers transplanted immature vision cells directly into the mouse retina. They noted that within weeks the cells began to integrate into the retina and the researchers, led by Prof Robin Ali in the university’s Institute of Ophthalmology, were able to show that vision began to return to the mice.

19 Apr 2012

ARVO to host presentation of results from two clinical trials on neovascular AMD

ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

19 Apr 2012

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

12 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012

Inflammasome involved in regulating Age-Related Macular Degeneration

Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular Degeneration.

9 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

CovalentMedical makes Focus MaculaPro available to general public

Focus MaculaPro is a leading macular health vitamin in the United States and is sold in more retina specialists' offices than any other eye vitamin on the market. Focus MaculaPro up until now has only been available to patients through their retina specialist. Now, however, Covalent Medical has made Focus MaculaPro available to the general public.

3 Apr 2012

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has received approval from the Australian Therapeutic Goods Administration (TGA) for EYLEA (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams (mg) via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

8 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.’s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow’s treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.

1 Mar 2012

UH's Eye Institute receives $5M Elisabeth Severance Prentiss Foundation gift

The Elisabeth Severance Prentiss Foundation again has demonstrated its commitment to University Hospitals (UH) with a $5 million gift for the Eye Institute. The gift will honor the late Benjamin L. Millikin, MD, husband of Julia Severance and the grandfather of Prentiss Foundation trustee Elisabeth Alexander.

18 Feb 2012

WSU's novel gene-therapy for blindness receives $250,000 FFB grant

Technology to restore vision through the use of a component of green algae - developed by a Wayne State University professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute - has attracted additional funding for therapy development.

16 Feb 2012

HB-EGF plays a critical role during retina regeneration

University of Michigan Health System research into the mechanisms by which zebrafish are able to regenerate damaged retinas after injury suggests new strategies for one day being able to do the same in humans - potentially allowing doctors to slow or reverse conditions like macular degeneration and glaucoma.

15 Feb 2012

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of data demonstrating the significant activity of aganirsen (GS-101, eye drops) in two important models of retinal neovascular disease, wet age-related macular degeneration (AMD) and ischemic retinopathy.

15 Feb 2012

Third patient dosed in Phase 1/2 SMD trial using RPE cells derived from hESCs

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

13 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

University of Kentucky researchers make major breakthrough in GA

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

ACT announces dosing of third patient in dry AMD Phase I/II trial

Regenerative medicine research offers hope for the blind

ARVO to host presentation of results from two clinical trials on neovascular AMD

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Inflammasome involved in regulating Age-Related Macular Degeneration

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

CovalentMedical makes Focus MaculaPro available to general public

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

UH's Eye Institute receives $5M Elisabeth Severance Prentiss Foundation gift

WSU's novel gene-therapy for blindness receives $250,000 FFB grant

HB-EGF plays a critical role during retina regeneration

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Third patient dosed in Phase 1/2 SMD trial using RPE cells derived from hESCs

Regeneron reports total revenues of $123.0M for fourth quarter 2011

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in